Linagliptin/Metformin 1 A Pharma (Metformin Hydrochloride, Linagliptin)

The linagliptin component blocks the enzyme dipeptidyl peptidase‑4, which prolongs the action of incretin hormones that stimulate insulin release and suppress glucagon. Metformin reduces the liver’s production of glucose and enhances the body’s sensitivity to insulin, together providing a dual approach to lower blood sugar.

The specific dose of Linagliptin/Metformin is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and prior response to therapy. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions without self‑adjusting the regimen.

Safety data for Linagliptin/Metformin during pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider after a thorough risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with single‑agent therapies, Linagliptin/Metformin offers a fixed‑dose combination that targets two distinct pathways, often resulting in greater HbA1c reduction and simplified dosing. Unlike sulfonylureas, it carries a lower intrinsic risk of hypoglycemia, and unlike insulin, it is administered orally, making it convenient for many patients.

Store Linagliptin/Metformin at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging to protect them from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

Linagliptin/Metformin is taken orally, usually once daily with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water. Patients should not crush, chew, or split the tablet unless specifically instructed.

The most serious adverse events include lactic acidosis, especially in patients with significant renal impairment, and severe hypoglycemia when used with insulin or sulfonylureas. Acute pancreatitis and severe allergic reactions are also rare but critical concerns that require immediate medical attention.

Linagliptin/Metformin is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to either component, or a history of lactic acidosis. Caution is also advised for individuals with significant hepatic disease, acute heart failure, or conditions predisposing to hypoxia.